BOSTON--(BUSINESS WIRE)--BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced that patients have been initially dosed in its Phase 2 ...
61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort 67% overall MMR and 55% MMR achievement by 24 weeks in all Phase 1b patients who had previously received 1 or 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results